‘High dose’ aprotinin and heparin-coated circuits: Clinical efficacy and inflammatory response

Vascular

Volumn 7, Issue 1, 1999, Pages 117-127

  Parolari, A ^a   Alamanni, F ^a   Gherli, T ^b   Salis, S ^c   Spirito, R ^a   Foieni, F ^c   Rossi, F ^a   Bertera, A ^a   Oddono, P ^a   Biglioli, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

aprotinin; cardiopulmonary bypass; heparin coated circuits; inflammation

Indexed keywords

APROTININ; C REACTIVE PROTEIN; HEPARIN; INTERLEUKIN 6;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTENSIVE CARE; MALE; PRIORITY JOURNAL;

APROTININ; C-REACTIVE PROTEIN; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY BYPASS; FEMALE; HEMATOLOGY; HUMANS; INTERLEUKIN-6; INTRAOPERATIVE PERIOD; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; SERINE PROTEINASE INHIBITORS;

EID: 0032935513     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721099900700122     Document Type: Article

References (39)

1. Butler J., Rocker G. M., Westaby S., Inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery, 1993, 55, 552–559.
2. Downing S. W., Edmunds H. L. Jr, Release of vasoactive substances during cardiopulmonary bypass. Annals of Thoracic Surgery, 1992, 54, 1236–1243.
3. Woodman R. C., Harker L. A., Bleeding complications associated with cardiopulmonary bypass. Blood, 1990, 76, 1680–1697.
4. Weerwind P. W., Maessen J. G., Van Tits L. J. K., et al, Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 1633–1641.
5. Gu Y. J., Van Oeveren W., Akkerman C., et al, Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Annals of Thoracic Surgery, 1993, 55, 917–922.
6. Jansen P. G. M., Te Veltius H., Huybregts R. A. J. M., et al, Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 829–834.
7. Ovrum E., Mollnes T. E., Fosse E., et al, Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 1623–1632.
8. Boonstra P. W., Gu Y. J., Akkerman C., et al, Heparin coating of an extracorporeal circuit partly improves after cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1994, 107, 209–292.
9. Royston D., High-dose aprotinin therapy: A review of the first five years' experience. Journal of Cardiothoracic and Vascular Anesthesiology, 1992, 6, 76–100.
10. Parolari A., Antona C., Gerometta P., et al, The effect of “high dose” aprotinin and other factors on bleeding and reoperations in adult coronary and valve operations: An analysis of 2190 patients during a five-year period (1987–1991). European Journal of Cardiothoracic Surgery, 1995, 9, 77–82.
11. Parolari A., Antona C., Rona P., et al, The effect of multiple blood conservation techniques on donor blood exposures in adult coronary and valve surgery performed with a membrane oxygenator: A multivariable analysis on 1310 patients. Journal of Cardiac Surgery, 1995, 10, 101–109.
12. Royston D., Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass. Journal of Cardiovascular Pharmacology, 1996, 27(Suppl. 1), S42-S49.
13. Wachtfogel Y. T., Kucich U., Hack C. E., et al, Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. Journal of Thoracic and Cardiovascular Surgery, 1993, 106, 1–10.
14. Wachtfogel Y. T., Hack C. E., Nuijens J. H., et al, Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. American Journal of Physiology, 1995, 268, H1352-H1357.
15. ACC/AHA guidelines and indications for coronary artery bypass graft-surgery. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation, 1991, 83, 1125–1173.
16. Mannucci L., Gerometta P., Mussoni L., et al, One month follow-up of haemostatic variables in patients undergoing aortocoronary bypass surgery: Effect of aprotinin. Thrombosis and Haemostasis, 1995, 73, 356–361.
17. Van Oeveren W., Harder M. P., Roozendal K. J., et al, Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1990, 99, 788–797.
18. Dietrich W., Barankay A., Hahnel C., Richter J. A., High-dose aprotinin in cardiac surgery: Three years' experience in 1784 patients. Journal of Cardiothoracic and Vascular Anesthesiology, 1992, 6, 324–327.
19. Dietrich W., Reducing thrombin formation during cardiopulmonary bypass: Is there a benefit of the additional anticoagulant action of aprotinin? Journal of Cardiovascular Pharmacology, 1996, 27(Suppl. 1), S50-S57.
20. Hill G. E., Alonso A., Spurzem J. R., et al, Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. Journal of Thoracic and Cardiovascular Surgery, 1995, 110, 1658–1662.
21. Fosse E., Moen O., Johnson E., et al, Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Annals of Thoracic Surgery, 1994, 58, 472–477.
22. Steinberg B. M., Grossi E. A., Schwartz D. S., et al, Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Annals of Thoracic Surgery, 1995, 60, 525–529.
23. Wagner W. R., Johnson P. C., Thompson K. A., Marrone G. C., Heparin-coated cardiopulmonary bypass circuits: Hemostatic alterations and postoperative blood loss. Annals of Thoracic Surgery, 1994, 58, 734–741.
24. Borowiec J., Thelin S., Bagge L., et al, Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1992, 104, 642–647.
25. Von Segesser L. K., Weiss B. M., Garcia E., et al, Reduced blood loss and transfusion requirements with low systemic heparinization: Preliminary clinical result in coronary artery revascularization. European Journal of Cardiothoracic Surgery, 1990, 4, 639–643.
26. Ovrum E., Holen E. A., Tangen G., et al, Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects. Annals of Thoracic Surgery, 1995, 60, 365–371.
27. Videm V., Svennevig J. L., Fosse E., et al, Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. Journal of Thoracic and Cardiovascular Surgery, 1992, 103, 806–813.
28. Butler J., Pillai R., Rocker G. M., et al, Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. Journal of Thoracic and Cardiovascular Surgery, 1993, 105, 25–30.
29. Nguyen D. M., Mulder D. S., Shennib H., Effect of cardiopulmonary bypass on circulating lymphocyte function. Annals of Thoracic Surgery, 1992, 53, 611–616.
30. Coze C. M., Glossary of cytokines. Bailliére's Clinical Hematology, 1994, 7, 1–15.
31. Hennein H. A., Ebba H., Rodriguez J. L., et al, Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. Journal of Thoracic and Cardiovascular Surgery, 1994, 108, 626–635.
32. Nosé P. S., Cytokines and reperfusion injury. Journal of Cardiac Surgery, 1994, 8(suppl.), 305–308.
33. Casey L. C., Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure. Annals of Thoracic Surgery, 1993, 56, S92-S96.
34. Van Snick J., Interieukin-6: An overview. Annual Review of Immunology, 1990, 8, 253–258.
35. Butler J., Chong G. L., Baigrie R. J., et al, Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. Annals of Thoracic Surgery, 1992, 53, 833–838.
36. Markewitz A., Faist F., Lang S., et al, Regulation of acute-phase response after cardiopulmonary bypass by immunomodulation. Annals of Thoracic Surgery, 1993, 55, 389–394.
37. Berger D., Bolke E., Huegel H., et al, New aspects concerning the regulation of post-operative acute phase reaction during cardiac surgery. Clinica Chimica Acta, 1995, 239, 121–130.
38. Steel D. M., Whitehead A. S., The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today, 1994, 15, 81–88.
39. Deodhar S. D., C-reactive protein: The best laboratory indicator available for monitoring disease activity. Cleveland Clinic Journal of Medicine, 1989, 56, 126–130.